Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The ongoing research and development of drugs by market players is expected to drive growth of the global antifungal drugs market. In 2015, Astellas Pharma Company launched Isavuconazole (Cresemba) drug in Europe for treatment of adult patients with invasive aspergillosis and mucormycosis, for whom amphotericin B use has been found inappropriate treatment option. This drug is available in the U.S and has a broad spectrum of intravenous and oral formulations and good results with patient safety. The company has received European marketing authorization for isavuconazole in all 28 EU member states, Iceland, Liechtenstein and Norway.

Similarly, in 2017, Pfizer Inc. launched its antifungal drug, Cresemba, in Spain by partnering with Basilea Pharmaceutical. Pfizer Inc. had planned to commercialize this drug in major EU markets and Austria.

Availability of generic drugs for treatment of fungal infections is another factor that is expected to drive growth of this market. For instance, in 2016, Ajanta Pharma launched voriconazole tablets (50-mg and 200-mg dose) in the U.S market. Voriconazole tablets are the generic equivalent of Pfizer’s Vfend, an antifungal drug.

Global Antifungal Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

The spread of the novel coronavirus has hampered growth of the healthcare industry. In December 2019, a cluster of pneumonia cases were reported by Chinese health authorities in China’s Wuhan City. The pneumonia causative agent was identified as a novel coronavirus named COVID-19. This virus spread rapidly across the globe causing a concerning number of fatalities. In March, 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The pandemic has slowed growth of the healthcare sector and led to a disturbance in the supply chain.

Moreover, governments across various countries have implemented nationwide lockdowns to curb the spread of COVID-19. Similarly, in various countries across the world, healthcare companies are facing problems of continuing their supply chain operations. The slowdown of in the supply chain has also impacted growth of the global antifungal drugs market.

The global antifungal drugs market is estimated to be valued at US$ 11,591.0 million in 2020 and is expected to exhibit a CAGR of 1.8% during the forecast period (2020-2027).

Fig. 1. Global Antifungal Drugs Market Share (%) Analysis, By Drug Type, 2020

Antifungal Drugs  | Coherent Market Insights

Global Antifungal Drugs Market- Restraints

Stringent government regulations are expected to restrain growth of the market. In 2020, the U.S FDA published Guidance on Antibacterial and Antifungal Drugs in which few sections focusing on establishing the safety and effectiveness of limited population antibacterial and antifungal drugs were added.

Additionally, increasing recall rate of pharmaceutical drugs is expected to restrain growth of this market. For instance, in August, 2020, Pharmaceutical Associates Inc. recalled around 7,416 bottles of nystatin oral suspension after the U.S Food and Drug Administration (FDA) Enforcement Report that showed out-of-specification results in 15-month test interval.

request-sample

Antifungal Drugs Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 11,591.0 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 1.8% 2027 Value Projection: US$ 13,132.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Echinocandins, Polyenes, Allylamines, Azoles, Others.
  • By Indication: Aspergillosis, Dermatophytosis, Candidiasis, Others.
  • By Dosage Form: Powders, Ointments, Drugs, Others.
Companies covered:

GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A., and Astellas Pharma, Inc.

Growth Drivers:
  • Continuous drug launches by market players is expected to drive growth of global antifungal drugs market
Restraints & Challenges:
  • Increasing recall of antifungal drugs

Global Antifungal Drugs Market: Opportunities

Increasing fungal resistance to antifungal drugs is expected to create significant opportunities for player to develop new drugs. Fungal resistance is of two types; microbiological and clinical. Microbiological resistance depends on established genetic alteration in the various fungi, and clinical resistance is due to host- or drug-related factors.

Global Antifungal Drugs Market: Regional Analysis

On the basis of region, the global antifungal drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to witness significant growth in the global antifungal drugs market, owing to health complications associated with candidiasis during and after pregnancy. According to the CDC, in 2015, vaginal candidiasis was the second most common type of vaginal infection after bacterial vaginal infection. The CDC estimates that around 1.4 million outpatient visits for vaginal candidiasis occur annually in the U.S.

 Additionally, the increasing research and development of novel medications showcasing broad-spectrum antifungal activity against invasive fungal infections caused due to Candida albicans. For instance, in October 2018, researchers at the American Society for Microbiology identified a compound alexidine dihydrochloride, which has the highest antifungal and anti-biofilm activity against a diverse range of fungal pathogens, and potential for use as a pan-antifungal drug.

Fig 2. Global Antifungal Drugs Market Value (US$ mn) & Y-o-Y Growth (%), 2017-2027

Antifungal Drugs  | Coherent Market Insights

Global Antifungal Drugs Market- Competitive Landscape

Key players operating in the global antifungal drugs market are GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merc k & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A. and Astellas Pharma, Inc.    

Anti-fungal drugs are used to treat fungal infections. Common fungal infections such as fungal nail infection, vaginal infection, and ringworm usually occur on the external surface of the body, while certain fungal invasive infections occur inside the tissue of body or in an internal organ such as lungs and brain. Fungal infection is usually associated with a weak immune system, such as people suffering from HIV and AIDS, and those undergoing high dosage chemotherapy who are more susceptible to invasive fungal infections. Anti-fungal drugs work against fungal infections by either killing the fungal cells or by inhibiting their growth. Anti-fungal drugs are broadly classified as topical antifungals, oral antifungals, intravenous antifungals, and intravaginal antifungal pessaries.

As per stats released by the Centers for Disease Control and Prevention (CDC), around 1 million people worldwide get infected by cryptococcal meningitis, which is a brain infection caused by fungus Cryptococcus and it subsequently leads to 625,000 deaths. These cases are mainly reported in sub-Saharan Africa. Also, the histoplasmosis infection mostly occurs in the U.S. and some portions of Central and South America. As per CDC’s study, histoplasmosis is a common infection observed in people with HIV and AIDS. In case of histoplasmosis, late diagnosis and treatment can be fatal.

Market Dynamics

The growing popularity of OTC drugs is expected to drive growth of the antifungal drugs market in near the future. OTC drugs are cost effective for patients and advertisement and promotion of antifungal drugs for dermal infections such as skin infections are favouring the growth of the market.

Furthermore, major players in the market are focused on various growth strategies such as collaborations and agreements in order to enhance their market presence. For instance, in June 2017, Basilea Pharmaceutica Ltd., a biopharmaceutical company, entered an agreement with Pfizer, Inc. and Avir Pharma, Inc. for the distribution of Beasilea’s antifungal treatments. Pfizer will manufacture and distribute drugs for treatment of life-threatening invasive mold infections in Russia, Israel, Europe (excluding Nordics), and Turkey.

Similarly, key players in the market are focused on various business strategies such as research and development in order to expand their product portfolio. Increasing drug development is expected to drive grow of this market. For instance, in January 2019, SCYNEXIS, Inc., a biotechnology company, announced positive interim result from first interim efficiency analysis of an ongoing FURI study. The development of this novel treatment is indicated for fungal treatment.

Key features of the study:

  • This report provides in-depth analysis of the global antifungal drugs market, market size (US$ mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
  • It profiles key players in the global antifungal drugs market  based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study are GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A. and Astellas Pharma, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global antifungal drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers of Infertility drugs and devices, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Antifungal Drugs Market, By Drug Type:
    • Echinocandins
    • Polyenes
    • Allylamines
    • Azoles
    • Others
  • Global Antifungal Drugs Market, By Indication:
    • Aspergillosis
    • Dermatophytosis
    • Candidiasis
    • Others
  • Global Antifungal Drugs Market, By Dosage Form:
    • Powders
    • Ointments
    • Drugs
    • Others
  • Global Antifungal Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Others
      • Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Others
      • Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Others
      • Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Others
      • Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Others
      • Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Echinocandins
        • Polyenes
        • Allylamines
        • Azoles
        • Others
      • By Indication:
        • Aspergillosis
        • Dermatophytosis
        • Candidiasis
        • Others
      • Dosage Form:
        • Powders
        • Ointments
        • Drugs
        • Others
  • Company Profiles
    • GlaxoSmithKline Plc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bayer AG
    • Abbott Laboratories
    • Merck & Co., Inc
    • Glenmark Pharmaceuticals Limited
    • Enzon Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Sanofi S.A.
    • Astellas Pharma, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snapshot, By Indication
      • Market Snapshot, By Dosage Form
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Market Trends
    • Key Developments
    • Impact Analysis
    • Mergers & Acquisitions
    • New Product Launch
    • Technology Overview
    • PEST Analysis
  4. Global Antifungal Drugs Market, by COVID-19 Impact Analysis
    • COVID 19 Impact Analysis
    • New Developments
  5. Global Antifungal Drugs Market, By Drug Type, 2016 – 2027, (US$ million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Echinocandins
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Polyenes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Allylamines
      •  Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Azoles
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Antifungal Drugs Market, By Indication, 2016 – 2027, (US$ million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Aspergillosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Dermatophytosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Candidiasis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Antifungal Drugs Market, By Dosage Form, 2016 – 2027, (US$ million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Powders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Ointments
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Antifungal Drugs Market, By Region, 2016– 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Drug Type, 2020 and 2027 (%)
      • Market Share Analysis, By Indication, 2020 and 2027 (%)
      • Market Share Analysis, By Dosage Form, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Share Analysis, By Drug Type, 2020 and 2027 (%)
      • Market Share Analysis, By Indication, 2020 and 2027 (%)
      • Market Share Analysis, By Dosage Form, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Share Analysis, By Drug Type, 2020 and 2027 (%)
      • Market Share Analysis, By Indication, 2020 and 2027 (%)
      • Market Share Analysis, By Dosage Form, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Share Analysis, By Drug Type, 2020 and 2027 (%)
      • Market Share Analysis, By Indication, 2020 and 2027 (%)
      • Market Share Analysis, By Dosage Form, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Share Analysis, By Drug Type, 2020 and 2027 (%)
      • Market Share Analysis, By Indication, 2020 and 2027 (%)
      • Market Share Analysis, By Dosage Form, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Share Analysis, By Drug Type, 2020 and 2027 (%)
      • Market Share Analysis, By Indication, 2020 and 2027 (%)
      • Market Share Analysis, By Dosage Form, 2020 and 2027 (%)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Share Analysis, By Drug Type, 2020 and 2027 (%)
      • Market Share Analysis, By Dosage Form, 2020 and 2027 (%)
      • Market Share Analysis, By Indication, 2020 and 2027 (%)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co., Inc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Glenmark Pharmaceuticals Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Enzon Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Gilead Sciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Astellas Pharma, Inc.  
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 28 market data tables and 25 figures on "Global Antifungal Drugs Market” - Forecast to 2027”

Frequently Asked Questions

The global antifungal drugs market is expected to register a CAGR of 1.8% during the forecast period (2020-2027).
The value of the global antifungal drugs market is estimated to be US$ 11,591.0 million in 2020.
The prominent players in the global antifungal drugs market are GlaxoSmithKline Plc, Bayer AG, Abbott Laboratories, Merck & Co., Inc, Glenmark Pharmaceuticals Limited, Enzon Pharmaceuticals, Inc., Pfizer Inc., Gilead Sciences, Inc., Sanofi S.A. and Astellas Pharma, Inc.
The global antifungal drugs market is expected to be valued at US$ 13,132.8 million in 2027.
North America is a major region in the global antifungal drugs market.
Launches drugs for fungal treatment is expected to drive the market growth.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner